Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug
Drug Shows Interim OS Gain – But Will It Be Enough?
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
